Richard Scranton
CIK 1709330 · View on SEC EDGAR ↗
First SEC filing: June 16, 2017 · Latest: June 16, 2017
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 8, 2019 | PCRX | S 10b5-1 | 19,448 | $45.00 | $875,160 | 16,061 Direct | -54.77% | Disposed | -46.5% (price as of 2026-08-20) |
| June 5, 2019 | PCRX | S 10b5-1 | 4,114 | $43.50 | $178,959 | 11,061 Direct | -27.11% | Disposed | -44.6% (price as of 2026-08-20) |
| June 4, 2019 | PCRX | S 10b5-1 | 2,852 | $42.66 | $121,666 | 15,175 Direct | -15.82% | Disposed | -43.5% (price as of 2026-08-20) |
| June 4, 2019 | PCRX | S 10b5-1 | 2,074 | $42.91 | $88,995 | 18,027 Direct | -10.32% | Disposed | -43.9% (price as of 2026-08-20) |
| June 3, 2019 | PCRX | S 10b5-1 | 15,510 | $43.21 | $670,187 | 20,101 Direct | -43.55% | Disposed | -44.3% (price as of 2026-08-20) |
| June 4, 2018 | PCRX | S | 1,367 | $33.02 | $45,138 | 12,226 Direct | -10.06% | Disposed | -27.1% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Nov. 8, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (4,750) | $25.37 | March 5, 2023 | 4,750 | Disposed |
| Nov. 8, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (14,698) | $10.81 | June 5, 2022 | 14,698 | Disposed |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (30,000) | $43.54 | June 5, 2029 | 30,000 | Acquired |
| June 3, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (12,500) | $10.81 | June 5, 2022 | 12,500 | Disposed |
| June 3, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (3,010) | $10.52 | March 2, 2022 | 3,010 | Disposed |
| June 13, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock (47,250) | $38.35 | June 13, 2028 | 47,250 | Acquired |
| May 2, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock (20,000) | $34.38 | May 2, 2028 | 20,000 | Acquired |
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (17,500) | $44.20 | June 14, 2027 | 17,500 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 11 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| June 16, 2017 | PCRX | Common Stock | 4,843 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (20,000) | 20,000 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (6,000) | 6,000 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (6,250) | 6,250 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (10,000) | 10,000 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (10,000) | 10,000 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (25,000) | 25,000 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (14,698) | 14,698 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (12,500) | 12,500 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (3,010) | 3,010 | Direct |
| June 16, 2017 | PCRX | Stock Option (Right to Buy)→ Common Stock (7,292) | 7,292 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2018 | $457,692 | $250,000 | $302,006 | $1,230,807 | — | — | $26,045 | $2,266,550 |
| 2017 | $378,462 | $150,000 | $386,750 | $770,418 | — | — | $966 | $1,686,596 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.